HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
<p><strong>Aims</strong>Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events.</p>&...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2013
|
| _version_ | 1797072867439935488 |
|---|---|
| author | HPS2-THRIVE Collaborative Group Jiang, L Hopewell, J Collins, R Armitage, J |
| author_facet | HPS2-THRIVE Collaborative Group Jiang, L Hopewell, J Collins, R Armitage, J |
| author_sort | HPS2-THRIVE Collaborative Group |
| collection | OXFORD |
| description | <p><strong>Aims</strong>Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events.</p><p><strong>Methods and results</strong> Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their low-density lipoprotein (LDL)-lowering therapy. The ability to remain compliant with ER niacin 2 g plus laropiprant 40 mg daily (ERN/LRPT) for ~1 month was then assessed in 38 369 patients and about one-third were excluded (mainly due to niacin side effects). A total of 25 673 patients were randomized between ERN/LRPT daily vs. placebo and were followed for a median of 3.9 years. By the end of the study, 25% of participants allocated ERN/LRPT vs. 17% allocated placebo had stopped their study treatment. The most common medical reasons for stopping ERN/LRPT were related to skin, gastrointestinal, diabetes, and musculoskeletal side effects. When added to statin-based LDL-lowering therapy, allocation to ERN/LRPT increased the risk of definite myopathy [75 (0.16%/year) vs. 17 (0.04%/year): risk ratio 4.4; 95% CI 2.6-7.5; P < 0.0001]; 7 vs. 5 were rhabdomyolysis. Any myopathy (definite or incipient) was more common among participants in China [138 (0.66%/year) vs. 27 (0.13%/year)] than among those in Europe [17 (0.07%/year) vs. 11 (0.04%/year)]. Consecutive alanine transaminase >3× upper limit of normal, in the absence of muscle damage, was seen in 48 (0.10%/year) ERN/LRPT vs. 30 (0.06%/year) placebo allocated participants.</p><p><strong>Conclusion</strong> The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastatin were higher. Despite the side effects of ERN/LRPT, among individuals who were able to tolerate it for ~1 month, three-quarters continued to take it for ~4 years. © 2013 The Author.</p> |
| first_indexed | 2024-03-06T23:13:52Z |
| format | Journal article |
| id | oxford-uuid:66709c95-09e8-43b8-ad3d-76c78a1cdc9c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:13:52Z |
| publishDate | 2013 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:66709c95-09e8-43b8-ad3d-76c78a1cdc9c2022-03-26T18:31:56ZHPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:66709c95-09e8-43b8-ad3d-76c78a1cdc9cEnglishSymplectic Elements at OxfordOxford University Press2013HPS2-THRIVE Collaborative GroupJiang, LHopewell, JCollins, RArmitage, J<p><strong>Aims</strong>Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events.</p><p><strong>Methods and results</strong> Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their low-density lipoprotein (LDL)-lowering therapy. The ability to remain compliant with ER niacin 2 g plus laropiprant 40 mg daily (ERN/LRPT) for ~1 month was then assessed in 38 369 patients and about one-third were excluded (mainly due to niacin side effects). A total of 25 673 patients were randomized between ERN/LRPT daily vs. placebo and were followed for a median of 3.9 years. By the end of the study, 25% of participants allocated ERN/LRPT vs. 17% allocated placebo had stopped their study treatment. The most common medical reasons for stopping ERN/LRPT were related to skin, gastrointestinal, diabetes, and musculoskeletal side effects. When added to statin-based LDL-lowering therapy, allocation to ERN/LRPT increased the risk of definite myopathy [75 (0.16%/year) vs. 17 (0.04%/year): risk ratio 4.4; 95% CI 2.6-7.5; P < 0.0001]; 7 vs. 5 were rhabdomyolysis. Any myopathy (definite or incipient) was more common among participants in China [138 (0.66%/year) vs. 27 (0.13%/year)] than among those in Europe [17 (0.07%/year) vs. 11 (0.04%/year)]. Consecutive alanine transaminase >3× upper limit of normal, in the absence of muscle damage, was seen in 48 (0.10%/year) ERN/LRPT vs. 30 (0.06%/year) placebo allocated participants.</p><p><strong>Conclusion</strong> The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastatin were higher. Despite the side effects of ERN/LRPT, among individuals who were able to tolerate it for ~1 month, three-quarters continued to take it for ~4 years. © 2013 The Author.</p> |
| spellingShingle | HPS2-THRIVE Collaborative Group Jiang, L Hopewell, J Collins, R Armitage, J HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title_full | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title_fullStr | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title_full_unstemmed | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title_short | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. |
| title_sort | hps2 thrive randomized placebo controlled trial in 25 673 high risk patients of er niacin laropiprant trial design pre specified muscle and liver outcomes and reasons for stopping study treatment |
| work_keys_str_mv | AT hps2thrivecollaborativegroup hps2thriverandomizedplacebocontrolledtrialin25673highriskpatientsoferniacinlaropipranttrialdesignprespecifiedmuscleandliveroutcomesandreasonsforstoppingstudytreatment AT jiangl hps2thriverandomizedplacebocontrolledtrialin25673highriskpatientsoferniacinlaropipranttrialdesignprespecifiedmuscleandliveroutcomesandreasonsforstoppingstudytreatment AT hopewellj hps2thriverandomizedplacebocontrolledtrialin25673highriskpatientsoferniacinlaropipranttrialdesignprespecifiedmuscleandliveroutcomesandreasonsforstoppingstudytreatment AT collinsr hps2thriverandomizedplacebocontrolledtrialin25673highriskpatientsoferniacinlaropipranttrialdesignprespecifiedmuscleandliveroutcomesandreasonsforstoppingstudytreatment AT armitagej hps2thriverandomizedplacebocontrolledtrialin25673highriskpatientsoferniacinlaropipranttrialdesignprespecifiedmuscleandliveroutcomesandreasonsforstoppingstudytreatment |